Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A global view on prophylaxis: possibilities and consequences.

A D Shapiro1

  • 1Indiana Hemophilia and Thrombosis Center, Indianapolis 46260, USA. ashapiro@ihtc.org

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Massive Intra-Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report.

Clinical case reports·2026
Same author

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

Blood advances·2020
Same author

The future of bypassing agents for hemophilia with inhibitors in the era of novel agents.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Optimizing bleed prevention throughout the lifespan: Womb to Tomb.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Journal of thrombosis and haemostasis : JTH·2017
Same journal

Prophylactic Factor Replacement Versus on-Demand Factor Replacement Following Primary Total Knee Arthroplasty in Patients With Hemophilia: A Retrospective Study With an Average 10-Year Follow-up.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Real-World Assessment of rVIII-SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High-Resource Settings.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Platelet Hyperreactivity May Contribute to Thrombotic Complications in Afibrinogenemia: A Case-Based Observation.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Predictors and Clinical Impact of Time to Diagnosis in Acquired Haemophilia A: An 11-Year Retrospective Cohort Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Prophylactic infusion therapy offers significant benefits for hemophilia patients, especially those with severe disease. However, its adoption is limited by cost and resource allocation challenges, particularly in developing nations.

Area of Science:

  • Hematology
  • Pharmacology
  • Public Health

Background:

  • Hemophilia management has evolved with prophylactic infusion therapy.
  • Severe hemophilia and associated arthropathy necessitate effective treatment strategies.
  • Prophylaxis aims to prevent bleeding episodes and long-term joint damage.

Purpose of the Study:

  • To review the benefits and current adoption of prophylactic infusion therapy in hemophilia care.
  • To highlight the challenges in implementing prophylaxis, particularly in resource-limited settings.
  • To discuss optimal prophylaxis regimens for factor VIII and factor IX deficiencies.

Main Methods:

  • Review of existing literature on hemophilia prophylaxis.
  • Analysis of treatment outcomes associated with different prophylactic regimens.

Related Experiment Videos

  • Examination of factors influencing the adoption of prophylaxis in clinical practice.

    • Main Results:

    • Primary prophylaxis initiated early (3x/week or every other day for FVIII deficiency, 2x/week for FIX deficiency) improves outcomes.
    • Despite proven benefits, primary prophylaxis is not universally adopted, even in developed countries.
    • Cost and resource allocation are major barriers to prophylaxis in developing countries, where on-demand therapy is often the norm.

    Conclusions:

    • Early initiation of prophylactic infusion therapy is crucial for optimal outcomes in severe hemophilia.
    • Wider adoption of prophylaxis is hindered by practical and economic challenges.
    • Addressing resource limitations is essential to improve access to prophylactic treatment for hemophilia patients globally.